AIDS Malignancy Consortium (AMC)

项目总结/摘要 艾滋病防治联盟（AMC）成立于1995年，一直走在前列 治疗和预防恶性肿瘤的干预措施的临床评价 人类免疫缺陷病毒（PLWH）感染者。AMC还研究了 癌症和癌前病变的PLWH在其临床试验的背景下，提供新的 进一步改善癌症的治疗和预防的见解。AMC进行了 100多项临床试验、调查和实验室研究，涉及8700多名艾滋病毒感染者， 相关癌症和癌前病变，包括应用 精确治疗和免疫治疗，影响PLWH的护理标准， 癌AMC已在美国、非洲、非洲和美国建立了42个核心临床试验中心网络， 和拉丁美洲唯一合格的执行其使命，创建了一个翻译网络， 支持AMC临床试验的科学家及其研究实验室，并开发了一种 职业发展计划，培养了新一代的医生和科学家 在艾滋病相关癌症方面有着独特的专业知识。将AMC扩展到以下地区的临床试验中心： 撒哈拉非洲和拉丁美洲是为了解决世界上 艾滋病毒和癌症的流行大幅增长，从而扩大了潜在的临床 其工作在全球范围内的影响。AMC还积极与艾滋病毒携带者和癌症幸存者接触 科学规划和社区外展，以确定社区的需求， 并传播有关AMC及其已完成和正在进行的研究的信息。的 许多重要临床医生和临床研究人员、实验室科学家的参与， 社区代表使AMC成为世界上主要的临床试验组织 致力于改善这一人群的癌症治疗和预防。我们提出 为了继续和扩大我们在这些领域的国内和国际临床试验工作， 包括锚试验;锚是一项大型随机研究，研究 常规筛查和治疗高度肛门鳞状上皮内病变， 预防浸润性肛门癌的发展以及发病率和死亡率的目标 与其诊断和治疗相关，从而建立新的诊断和 治疗范例

PROJECT SUMMARY/ABSTRACT The AIDS Malignancy Consortium (AMC) was established in 1995 and has been at the forefront of the clinical evaluation of interventions for the treatment and prevention of malignancies in people living with the human immunodeficiency virus (PLWH). AMC also studies the biology of cancers and precancerous lesions in PLWH in the context of its clinical trials, providing new insights on further improving the treatment and prevention of cancer. The AMC has conducted over 100 clinical trials, surveys and laboratory studies involving over 8700 patients with HIV- associated cancers and precancerous lesions since its inception, including application of precision therapeutics and immunotherapy, impacting the standard of care for PLWH and cancer. AMC has established a network of 42 core clinical trial sites in the United States, Africa, and Latin America uniquely qualified carry out its mission, created a network of translational scientists and their research laboratories that support AMC clinical trials, and developed a career enhancement program that has fostered a new generation of physicians and scientists with unique expertise in HIV-associated cancers. Expansion of AMC to clinical trials sites in sub- Saharan Africa and Latin America is designed to address regions of the world where the epidemic of HIV and cancer has grown substantially, thereby amplifying the potential clinical impact of its work to a global scale. AMC has also actively engaged PLWH and cancer survivors in its scientific planning and community outreach in order to identify the needs of the community, and disseminate information about AMC and its completed and ongoing research. The participation of many of the key clinicians and clinical researchers, laboratory scientists, and community representatives has made AMC the principal clinical trials group in the world dedicated to improving the treatment and prevention of cancers in this population. We propose to continue and expand our domestic and international clinical trials work in these areas, including the ANCHOR trial; ANCHOR is a large randomized study investigating the role of routine screening for and treatment of high-grade anal squamous intraepithelial lesions, with the goal of preventing development of invasive anal cancer and the morbidity and mortality associated with its diagnosis and treatment, thereby establishing new diagnostic and therapeutic paradigm.